Nuvation Bio, the biotech startup focused on developing next-generation oncology therapies, has raised $275M in funding from investors that include EDBI, Aisling Capital, Omega Funds, Altitude Life Science Ventures, Pavilion Capital, and The Baupost Group. Nuvation Bio was founded by David Hung and Gary Hattersley in 2018.
The AlleyWatch audience is driving progress and innovation on a global scale. With its regional media properties, AlleyWatch serves as the highway for technology and entrepreneurship. There are a number of options to reach this audience of the world’s most innovative organizations and startups at scale including sponsoring a piece like this, which will be read by the vast majority of key influencers in the entrepreneurial universe. Find out more here.